News

Zacks Investment Research on MSN3d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Kymera’s partnerships with Sanofi and Gilead drive value
Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.
Nasdaq3d
Kymera Therapeutics Announces $250.8 Million Public Offering of Common Stock and Pre-Funded Warrants - Nasdaq
Kymera Therapeutics, Inc. announced the pricing of its public offering of $250.8 million, consisting of 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants for ...
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Morningstar3d
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics Announces Pricing of $250 Million Public Offering Provided by GlobeNewswire Jun 27, 2025, 3:56:15 AM. WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera ...